首页 | 本学科首页   官方微博 | 高级检索  
检索        

《中国药典》2020年版昆虫纲药用动物养殖研究进展
引用本文:尹馨雪,吴淇,鞠春梅,张辉,李志成.《中国药典》2020年版昆虫纲药用动物养殖研究进展[J].中国现代中药,2022,24(9):1625-1632.
作者姓名:尹馨雪  吴淇  鞠春梅  张辉  李志成
作者单位:1.长春中医药大学,吉林 长春 130117;2.吉林省东北亚生物科技有限公司,吉林 长春 130119
基金项目:国家林业和草原局:药用野生动物物种和人工繁育技术现状调查评估项目(20210718)
摘    要:分析《中华人民共和国药典》(以下简称《中国药典》) 2020年版昆虫纲药用动物养殖研究的现状,统计《中国药典》 2020年版昆虫纲动物药的收载情况、含有昆虫纲动物药的中成药品种。对收载动物的地理分布与栖息环境,生活习性与活动规律,养殖技术中养殖方法与设施、饲养饵料、疾病防治、养殖成熟度进行分类对比论述。《中国药典》 2020年版共收载13种涉及昆虫纲药用动物的品种。其中,含土鳖虫中成药品种数量34种,在成方制剂和单味制剂中占比2.12%;含五倍子数量为8种,占比0.50%;含冬虫夏草数量为1种,占比0.06%;含虫白蜡数量为1种,占比0.06%;含桑螵蛸数量为3种,占比0.19%;含斑蝥数量为2种,占比0.12%;含蜂房数量为1种,占比0.06%;含蜂蜡数量为13种,占比0.81%;含蜂蜜数量为19种,占比1.18%;含蝉蜕数量为38种,占比2.36%;含僵蚕数量为35种,占比2.18%。《中国药典》 2020年版所载昆虫纲药用动物地鳖、冬虫夏草养殖评估为扩养;白蜡虫、中华蜜蜂、意大利蜂养殖评估为初养;九香虫、斑蝥、角倍蚜、螳螂、蝉蜕、僵蚕养殖评估为试养;冀地鳖、日本长脚胡蜂、异蝮胡蜂...

关 键 词:《中国药典》  昆虫纲  养殖  研究进展
收稿时间:2021/11/8 0:00:00

Research Progress on the Breeding of Medicinal Animals of Insecta in Chinese Pharmacopoeia (2020 Edition)
YIN Xin-xue,WU Qi,JU Chun-mei,ZHANG Hui,LI Zhi-cheng.Research Progress on the Breeding of Medicinal Animals of Insecta in Chinese Pharmacopoeia (2020 Edition)[J].Modern Chinese Medicine,2022,24(9):1625-1632.
Authors:YIN Xin-xue  WU Qi  JU Chun-mei  ZHANG Hui  LI Zhi-cheng
Institution:1.Changchun University of Chinese Medicine, Changchun 130117, China;2.Northeast Asia Biotechnology Co., Ltd., Changchun 130119, China
Abstract:Through analyzing the current status of research on the breeding of medicinal animals in the class Insecta in Chinese Pharmacopoeia (2020 Edition), the insect drugs in Chinese Pharmacopoeia (2020 Edition) were reviewed, and the Chinese patent medicines containing insect drugs were counted. The geographical distribution, habitat environment, living habits, activity rules, breeding methods and facilities, diet, disease control, and breeding technology maturity of the animals were summarized and compared.Chinese Pharmacopoeia (2020 Edition) listed 13 species of medicinal animals of Insecta. Specifically, 34 Chinese patent medicines contain Eupolyphaga Steleophaga, accounting for 2.12%; 8 Chinese patent medicines contain Galla Chinensis, accounting for 0.50%; 1 Chinese patent medicine contains Cordyceps, accounting for 0.06%; 1 Chinese patent medicine contains Cera Chinensis, accounting for 0.06%; 3 Chinese patent medicines contain Mantidis Ootheca, accounting for 0.19%; 2 Chinese patent medicines contain Mylabris, accounting for 0.12%; 1 Chinese patent medicine contains Vespae Nidus, accounting for 0.06%; 13 Chinese patent medicines contain Cera Flava, accounting for 0.81%; 19 Chinese patent medicines contain Mel, accounting for 1.18%; 38 Chinese patent medicines contain Cicadae Periostracum, accounting for 2.36%; 35 Chinese patent medicines contain Bombyx Batryticatus, accounting for 2.18%. The breeding of the medicinal animals of Insecta in Chinese Pharmacopoeia (2020 Edition) was evaluated. Specifically, it is suggested to expand the breeding of Eupolyphaga sinensis and Hepialus armoricanus, primarily breed Ericerus pela, Apis cerana, and Apis mellifera ligustica, and try the breeding of Aspongopus chinensis, Mylabris, Schlechtendalia chinensis, Mantodea, Cryptotympana pustulata, and Bombyx mori. There has been no report on Polyphaga plancyi, Polistes japonicas, Parapolybia indica, or Polistes olivaceus.
Keywords:Chinese Pharmacopoeia  Insecta  breeding  research progress
点击此处可从《中国现代中药》浏览原始摘要信息
点击此处可从《中国现代中药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号